Limitations of Subgroup Safety Analyses for Drug–Drug Interaction Evaluation: Insights from the Talazoparib P‐gp Inhibitor Case

Documenti analoghi

• Talazoparib Formulation Bridging in Cancer Patients—Challenges and the Critical Role of Model‐Informed Drug Development in Approval Despite Failed Bioequivalence
  di: Diane Wang, et al.
  Pubblicazione: (2025)
• In Vitro and Clinical Evaluations of UGT1A1‐, P‐gp‐, OATP1B1‐, and BCRP‐Mediated Drug–Drug Interactions of Belumosudil, a Potent ROCK2 Inhibitor
  di: Olivier Schueller, et al.
  Pubblicazione: (2025)
• Population Pharmacokinetics Analysis of Talazoparib and Enzalutamide Combination Therapy for Patients With Metastatic Castration‐Resistant Prostate Cancer
  di: Mark Hadigol, et al.
  Pubblicazione: (2025)
• Elranatamab Exposure–Safety Analysis in Relapsed or Refractory Multiple Myeloma
  di: Pooneh Soltantabar, et al.
  Pubblicazione: (2025)
• A Phase 1 Study to Evaluate the Potential Drug–Drug Interaction Between Islatravir and Lenacapavir
  di: Haeyoung Zhang, et al.
  Pubblicazione: (2026)